{
    "nct_id": "NCT04313504",
    "official_title": "An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients",
    "inclusion_criteria": "* Histologically, cytologically, or radiographically confirmed recurrent or metastatic non cutaneous HNSCC for which there are no surgical or radiation curative options.\n* ECOG performance status â‰¤2\n* Patients must be able to swallow pills\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Nasopharyngeal and salivary gland tumors\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy with the exception of alopecia\n* Prior exposure to both immunotherapy drugs (PD-1, PDL-1, CTLA-4 inhibitors) and PARP inhibitors. Single exposure to either immunotherapy or PARP inhibitors is allowable.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to niraparib or dostarlimab.\n* Patients with uncontrolled intercurrent illness.\n* Requirement of any use of steroids greater than the equivalent of 10mg prednisone daily is not allowed.",
    "miscellaneous_criteria": ""
}